Transcriptomics Market Size (2022-2030) | Share, Trends,
Pune, July 25, 2022 (GLOBE NEWSWIRE) — The Global transcriptomics market it is expected that the clock ~€ 14.17 billion by 2030 due to the phenomenal expansion of the fields of biopharmaceutical research and development. AAccording to the latest trend report published by Growth Plus, titled “Transcriptomics Market By Product (Reagents, Software, Instruments), By Application (Drug Discovery, Clinical Diagnostics, Toxicogenomics), By Technology (Microarray, Chain Reaction By polymerase, sequencing), by End User (pharmaceutical and biotech companies, CROs, hospitals and diagnostic centers, academic and research institutes) – Global outlook and forecast 2022-2030”
The study of RNA molecules in the cell is known as transcriptomics. RNA information is derived from DNA and consists of information about protein production. The identification, classification and treatment of new diseases, personalized medicine as a dominant trend in the health sector, the increasing use of RNA sequencing and government funding of omics are some of the factors that stimulate the market.
Get a sample PDF of the report – https://growthplusreports.com/inquiry/request-sample/transcriptomics-market/7733
The use of RNA sequencing is increasing dramatically in all areas of life sciences and is becoming an essential approach for transcriptomics research. RNA sequencing has completely transformed transcriptome analysis, allowing the quantification of gene expression levels and allele-specific expression in a single study, as well as the affinity of new genes, isoforms splicing, fusion transcripts and extraordinary research in the world of non-RNA coding. The demand for RNA sequencing in research field is increasing as it uses highly scientific study to obtain genetic information even though it is highly sensitive to genes which produce very smooth output while using this technology . In terms of rare diseases, RNA sequencing has enormous diagnostic power, ranging from rare muscle conditions to mitochondrial disorders such as mitochondrial depletion syndrome and Kearns-Sayre syndrome. Apart from traditional applications, RNA sequencing is also used to solve problems caused by microarrays. For example, with a lack of control over the pool of transcripts analyzed and differences caused by hybridization, RNA sequencing can be used to sequence and quantify transcriptional outputs from single cells or thousands of samples (RNA -seq).
Both the public and private sectors are investing heavily in life science research and development. Transcriptomics technique is used to get an accurate understanding of the genome or transcriptome, which is necessary for any new drug development, disease analysis or any other research work in which the idea of the genome of a specific organism is important to know because only then can the work be carried out. Funding for research institutes or pharmaceutical and biotechnology companies is increasing because after the pandemic, the governments of almost all nations are aware of any kind of disease or epidemic. Funding for cancer research is also increasing. Most public funds go to breast cancer and childhood cancer. In 2019, the US government’s NIH invested $460 million in breast cancer, which grew to $3.5 billion in 2022.
Get a Sample Copy of the Transcriptomics Market Report 2022
Excerpts from “By region”
Geographically, the Global Transcriptomics Market is classified into:-
- North America
- Asia-Pacific (APAC)
- Rest of the world (right-of-way)
Due to factors such as increasing drug discovery research for many chronic diseases such as cancer, high government investments in many new life science based studies, extensive use of this technical by many pharmaceutical and biotechnology companies and the presence of many pharmaceutical and biotechnology laboratories. companies in this region, the North America region is expected to dominate the global transcriptomics market. After North America, Europe is also experiencing rapid growth, due to the rapid development of transcriptomics application areas and increasing collaborations. For example, the Italian Institute of Technology and the European Molecular Biology Laboratory signed a collaboration contract in April 2021. This agreement aims to expand their database and facilitate the sharing of research funds. The Italian Institute of Technology also recently launched the RNA program, which focuses on non-coding RNAs and an increased number of new drug discoveries.
Excerpts from “Competitive Landscape”
Some of the Major Players Operating in the Global Transcriptomics Market are:-
- Bio-Rad Laboratories Inc.
- Thermo Fisher Scientific Inc.
- Agilent Technologies Inc.
- Illumina Inc.
- Qiagen AG
- F. Hoffman La Roche Ltd.
- Eurofins Scientific SE
- Fluidigm Company
- Merck KgaA
- Acobiom and CD Genomics
Transcriptomics Market Segmentation:-
- drug discovery
- Clinical diagnosis
- Polymerase chain reaction
End User Perspectives:
- Pharmaceutical and biotechnology companies
- Hospitals and diagnostic centers
- Academic and research institutes
Report Scope and Segmentation:
|Market size in 2021||~$4.5 billion|
|Revenue forecasts in 2030||~$14.17 billion|
|Rate of growth||CAGR of ~13.50% from 2022 to 2030|
|Base year for the estimate||2021|
|Segments Covered||Products, Application, Technology, End User|
|Regional scope||North America, Europe, Asia-Pacific and Rest of the World (ROW)|
VALUE PROPOSITIONS RELATED TO THE REPORT:
- Fueled by free analyst hours and expert interviews with every report
- Comprehensive quantitative and qualitative information at segment and sub-segment level
- Trends and perspectives of the impact of Covid 19
- Granular information at global/regional/country level
- In-depth insights into market dynamics (drivers, restraints, opportunities) and business environment
- Global coverage of the competitive landscape
- Winning imperatives
- Comprehensive coverage of “strategic developments” recorded by major market players
- Distributor Landscape Assessment
- Pricing information
- Customer evaluation
- Analysis of investments and initiatives
- ‘Company Profile’ of key players
Purchase This Report (Price $5950 for Single User License) – https://growthplusreports.com/checkout?_token=KMLNUv8wtKI7V0NHgJCQQ0GRbbtGIwdRKuUi7LUD&report_id=7733&license=Single&submit=
Growth+Reports is part of GRG Health, a global healthcare knowledge services company. We are proud members of the EPhMRA (European Pharmaceutical Marketing Research Association).
The Growth+ portfolio of services leverages our core capabilities in secondary and primary research, market modeling and forecasting, benchmarking, analysis and strategy formulation to help clients create scalable and game-changing solutions. that prepare them for future growth and success.
We have been recognized by the prestigious CEO Magazine as “2020’s Most Innovative Healthcare Market Research Company”.